At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Dipyridamole +1 moredrug
Likely dose
Dipyridamole 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987
In Brief
A Phase 2 clinical trial evaluating Dipyridamole and Placebo, then Dipyridamole for HIV Infection. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if Dipyridamole (DP) will decrease inflammation in HIV-1-infected individuals who are already on antiretroviral treatment and have a low viral load.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection
CountriesUnited States
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartJul 2014
Primary CompletionOct 2017
Study CompletionNov 2017
TodayJul 2026
First PostedApr 23, 2014
Enrollment StartJul 1, 2014
Primary CompletionOct 1, 2017
Study CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.2 years ago
Interventions
Dipyridamoledrug
Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
Placebo, then Dipyridamoledrug
Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24